A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...
Genomic alterations in circulating tumor DNA (ctDNA) and response to telisotuzumab adizutecan (ABBV-400) treatment in patients (pts) with colorectal cancer (CRC). A comparison of real-world outcomes ...
Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions The ...
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company ...
High-grade gliomas, including glioblastomas, are aggressive cancers of the brain that usually recur despite standard treatment, including radiation therapy. These mechanisms conferring persistence to ...
Suzhou Zion Pharma Technology Co Ltd. has divulged serine-protein kinase ATM (ataxia telangiectasia mutated) inhibitors reported to be useful for the treatment of cancer.
A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM ...
Searching for ways to extend the survival benefit of targeted therapies, a team led by researchers has identified a potential new tactic to disrupt the repair mechanism that cancer cells use after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback